• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Sol-Gel Technologies Ltd.

    4/29/25 1:35:47 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLGL alert in real time by email
    S-8 1 zk2533073.htm S-8

    Registration No. ______________
     
    As filed with the Securities and Exchange Commission on April 29, 2025

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549



    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933



    Sol-Gel Technologies Ltd.
    (Exact name of registrant as specified in its charter)

    State of Israel
    (State or other jurisdiction of
    incorporation or organization)
    Not Applicable
    (I.R.S. Employer Identification No.)

    Sol-Gel Technologies Ltd.
    7 Golda Meir St., Weizmann Science Park
    Ness Ziona, 7403650, Israel
    Tel: +972-8-931-3433
    (Address of Principal Executive Offices) (Zip Code)

    Sol-Gel Technologies Ltd. 2024 Share Incentive Plan
     (Full title of the plan)
     
    Puglisi & Associates
    850 Library Avenue, Suite 204
    Newark, Delaware
    (Name and address of agent for service)
     
    +1 (302) 738-6680
    (Telephone number, including area code, of agent for service)
     
    Copies to:

    Jeffrey Schultz
    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
    919 Third Avenue
    New York, New York 10022
    Tel: + 1 212-935-3000
    Perry Wildes
    Goldfarb Gross Seligman & Co.
    One Azrieli Center
    Tel Aviv 6702100, Israel
    Tel: +972 (3) 607-4444

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.  See the definitions of "large accelerated filer", "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
     
    Large Accelerated Filer ☐
    Non-Accelerated Filer ☒
    Accelerated Filer ☐
    Smaller reporting company ☐
    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.


    PART I
     
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
     
    ITEM 1.          PLAN INFORMATION.*
     
    ITEM 2.          REGISTRANT INFORMATION AND EMPLOYEE PLAN ANNUAL INFORMATION. *
    ___________________
     
    * Information required by Part I to be contained in the Section 10(a) prospectus is omitted from this registration statement in accordance with Rule 428 under the Securities Act of 1933, as amended, or the Securities Act, and the Introductory Note to Part I of Form S-8.
     
     PART II
     
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
     
    ITEM 3.          INCORPORATION OF DOCUMENTS BY REFERENCE
     
    The following documents filed with or furnished to the Securities and Exchange Commission (the “Commission”) by Sol-Gel Technologies Ltd., a company organized under the laws of Israel (the “Company” or the “Registrant”), are incorporated herein by reference and made a part hereof:
     
     
    (a)
    the Company’s Annual Report for the year ended December 31, 2024 on Form 20-F filed with the Commission on April 29, 2025;
     
     
    (b)
    the Company's reports on Form 6-K furnished to the Commission on February 18, 2025, April 1, 2025 and April 17, 2025 (in each case only to the extent provided in such Form 6-K);  and
     
     
    (c)
    the description of the Company’s ordinary shares, par value NIS 0.1 per share, included in the registration statement on Form 8-A filed on January 26, 2018 (File No. 001-38367) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.
     
    All documents or reports subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, and to the extent designated therein, certain reports on Form 6-K, furnished by the Company, after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities offered hereby then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents or reports; provided, however, that documents and reports, or portions thereof, which are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement in a document or report incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document or report which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    ITEM 4.          DESCRIPTION OF SECURITIES
     
    Not applicable.
     
    ITEM 5.          INTERESTS OF NAMED EXPERTS AND COUNSEL
     
    Not applicable.


    ITEM 6.          INDEMNIFICATION OF DIRECTORS AND OFFICERS

    Under the Companies Law, a company may not exculpate an office holder from liability for a breach of the fiduciary duty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles of association include such a provision. The company may not exculpate in advance a director from liability arising due to the breach of his or her duty of care in the event of a prohibited dividend or distribution to shareholders. 
     
    Under the Companies Law and the Israeli Securities Law, 5728-1968, or the Securities Law, a company may indemnify an office holder in respect of the following liabilities, payments and expenses incurred for acts performed by him or her as an office holder, either in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification:  

     
    •
    a monetary liability incurred by or imposed on the office holder in favor of another person pursuant to a court judgment, including pursuant to a settlement confirmed as judgment or arbitrator’s decision approved by a competent court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company’s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria;
     
     
    •
    reasonable litigation expenses, including reasonable attorneys’ fees, which were incurred by the office holder as a result of an investigation or proceeding filed against the office holder by an authority authorized to conduct such investigation or proceeding, provided that such investigation or proceeding was either (i) concluded without the filing of an indictment against such office holder and without the imposition on him of any monetary obligation in lieu of a criminal proceeding; (ii) concluded without the filing of an indictment against the office holder but with the imposition of a monetary obligation on the office holder in lieu of criminal proceedings for an offense that does not require proof of criminal intent; or (iii) in connection with a monetary sanction;
     
     
    •
    a monetary liability imposed on the office holder in favor of a payment for a breach offended at an Administrative Procedure (as defined below) as set forth in Section 52(54)(a)(1)(a) to the Securities Law;
     
     
    •
    expenses expended by the office holder with respect to an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys’ fees;
     
     
    •
    reasonable litigation expenses, including attorneys’ fees, incurred by the office holder or which were imposed on the office holder by a court (i) in a proceeding instituted against him or her by the company, on its behalf, or by a third party, (ii) in connection with criminal indictment of which the office holder was acquitted, or (iii) in a criminal indictment which the office holder was convicted of an offense that does not require proof of criminal intent; and
     
     
    •
    any other obligation or expense in respect of which it is permitted or will be permitted under applicable law to indemnify an office holder, including, without limitation, matters referenced in Section 56H(b)(1) of the Securities Law.
     
    An “Administrative Procedure” is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.
     

    Under the Companies Law and the Securities Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder if and to the extent provided in the company’s articles of association:
     
     
    •
    a breach of the fiduciary duty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;
     
     
    •
    a breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder;
     
     
    •
    a monetary liability imposed on the office holder in favor of a third party;
     
     
    •
    a monetary liability imposed on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section 52(54)(a)(1)(a) of the Securities Law; and
     
     
    •
    expenses incurred by an office holder in connection with an Administrative Procedure, including reasonable litigation expenses and reasonable attorneys’ fees.
     
    Under the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:
     
     
    •
    a breach of the fiduciary duty, except for indemnification and insurance for a breach of the fiduciary duty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;
     
     
    •
    a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;
     
     
    •
    an act or omission committed with intent to derive illegal personal benefit; or
     
     
    •
    a fine or forfeit levied against the office holder.
     
    Under the Companies Law, exculpation, indemnification and insurance of office holders must be approved by the compensation committee and the board of directors and, with respect to directors or controlling shareholders, their relatives and third parties in which controlling shareholders have a personal interest, also by the shareholders. 
     
    Our amended and restated articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by law. Our office holders are currently covered by a directors’ and officers’ liability insurance policy. As of the date of this annual report, no claims for directors’ and officers’ liability insurance have been filed under this policy and we are not aware of any pending or threatened litigation or proceeding involving any of our office holders, including our directors, in which indemnification is sought. 
     
    We have entered into agreements with each of our current office holders exculpating them from a breach of their duty of care to us to the fullest extent permitted by law, subject to limited exceptions, and undertaking to indemnify them to the fullest extent permitted by law, subject to limited exceptions, including, with respect to liabilities resulting from this offering, to the extent that these liabilities are not covered by insurance. This indemnification is limited, with respect to any monetary liability imposed in favor of a third party, to events determined as foreseeable by the board of directors based on our activities. The maximum aggregate amount of indemnification that we may pay to our office holders based on such indemnification agreement is the greater of (1) 25% of our shareholders’ equity pursuant to our audited financial statements for the year preceding the year in which the event in connection of which indemnification is sought occurred, and (2) $40 million (as may be increased from time to time by shareholders’ approval). Such indemnification amounts are in addition to any insurance amounts. Each office holder who agrees to receive this letter of indemnification also gives his approval to the termination of all previous letters of indemnification that we have provided to him or her in the past, if any. However, in the opinion of the SEC, indemnification of office holders for liabilities arising under the Securities Act is against public policy and therefore unenforceable.

    ITEM 7.          EXEMPTION FROM REGISTRATION CLAIMED

    Not applicable.


    ITEM 8.          EXHIBITS

    Exhibit
    Number
    Description
    4.1*
    Amended and Restated Memorandum of Association of the Registrant.
    4.2**
    Amended and Restated Articles of Association of the Registrant.
    5.1
    Opinion of Goldfarb Gross Seligman  & Co.
    23.1
    Consent of Goldfarb Gross Seligman & Co. (included in Exhibit 5.1).
    23.2
    Consent of Kesselman & Kesselman, Member Firm of PricewaterhouseCoopers International Limited.
    24.1
    Power of Attorney (included on signature page).
    99.1***
    Sol-Gel Technologies Ltd. 2024 Share Incentive Plan
    107
    Filing Fee Table

    * Incorporated herein by reference to Exhibit 3.1 to the Registrant's Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on January 23, 2018.
     
    ** Incorporated herein by reference to Exhibit 1.2 to the Registrant's Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 13, 2024.

    *** Incorporated herein by reference to Appendix A of Exhibit 99.1 of the Current Report on Form 6-K submitted to the Securities and Exchange Commission on September 25, 2024.


    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Ness Ziona, State of Israel, on this 29th day of April, 2025.
     
     
    Sol-Gel Technologies Ltd.
     
    By: /s/ Moshe Arkin
    Moshe Arkin
    Chief Executive Officer

    POWER OF ATTORNEY
     
    KNOW ALL BY THESE PRESENTS, that each individual whose signature appears below constitutes and appoints Moshe Arkin and Eyal Ben-Or, and each of them, his true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign this registration statement and any and all future amendments (including post-effective amendments) to the registration statement, and to file the same with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or any of them, or their or his substitute, may lawfully do or cause to be done by virtue hereof.
     
    Pursuant to the requirements of the Securities Act of 1933, as amended this registration statement has been signed by the following persons in the capacities and on the dates indicated:
     
    Signatures
    Title
    Date
     
     
     
    /s/ Moshe Arkin
    Moshe Arkin
    Executive Chairman, Board of Directors and Interim CEO
    April 29, 2025
     
     
     
    /s/ Eyal Ben-Or
    Eyal Ben-Or
    Chief Financial Officer 
    April 29, 2025
     
     
     
    /s/ Itai Arkin
    Itai Arkin
    Director
    April 29, 2025
     
     
     
    /s/ Yuval Yanai
    Yuval Yanai
    Director 
    April 29, 2025
     
     
     
    /s/ Hanna Lerman
    Hani Lerman
    Director  
    April 29, 2025
     
     
     
    /s/ Ran Gottfried
    Ran Gottfried
    Director
    April 29, 2025
     
     
     
    /s/ Sharon G. Kochan
    Sharon G. Kochan
    Director
    April 29, 2025


    Signature of Authorized Representative in the United States
     
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant’s duly authorized representative has signed this Registration Statement on Form F-3 on this 29th day of April, 2025.

    Puglisi & Associates
    Authorized U.S. Representative

    By: /s/ Donald J. Puglisi
    Name: Donald J. Puglisi
    Title: Managing Director


    Get the next $SLGL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLGL

    DatePrice TargetRatingAnalyst
    8/19/2024$6.00 → $4.00Strong Buy → Outperform
    Raymond James
    10/21/2022$5.50Hold
    Jefferies
    11/15/2021$21.00 → $20.00Buy
    HC Wainwright & Co.
    11/12/2021$23.00 → $21.00Strong Buy
    Raymond James
    7/28/2021$20.00 → $21.00Buy
    HC Wainwright & Co.
    7/12/2021$21.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SLGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $5,800 worth of Ordinary Shares (100 units at $58.00) (SEC Form 4)

    4 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)

    2/4/26 4:05:33 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. bought $5,705 worth of Ordinary Shares (100 units at $57.05) (SEC Form 4)

    4 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)

    1/29/26 4:16:32 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. bought $187,356 worth of Ordinary Shares (3,324 units at $56.36) (SEC Form 4)

    4 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)

    1/23/26 5:42:51 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease

    NESS ZIONA, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today provided an update following the unblinding of clinical data from its vehicle-controlled proof-of-concept Phase 1b study of SGT-210 on Darier disease. Following unblinding, the data from the vehicle-controlled Phase 1b proof-of-concept study did not show differentiation between SGT-210 and vehicle on the study's efficacy assessments. Mr. Mori Arkin, Executive Chairman of Sol-Gel, stated: "After unblinding the clinical data from our trial, the study did not demonstrate a signal of superiority o

    12/17/25 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

    Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug's commercial potentialIn September 2025, Sol-Gel announced Health Canada approval of EPSOLAYSol-Gel signed an additional agreement with Viatris covering Australia and New Zealand for both EPSOLAY and TWYNEO NESS ZIONA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced financial results for the third quarter ending September 30, 2025, and provided a corporate update. Q3 2025 and Recent C

    11/20/25 7:30:00 AM ET
    $SLGL
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Announces Health Canada Approval of EPSOLAY®

    NESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, a Phase-1b, double blinded clinical trial of SGT-210 (erlotinib ointment, 5%) on Darier disease patients and with two approved large-category dermatology products, TWYNEO and EPSOLAY, announced today that on August 27, 2025 Health Canada issued a Notice of Compliance (NOC) for EPSOLAY for the treatment of inflammatory lesions of rosacea in adults. This approval comes as a result of Sol-Gel's partnership with Searchlig

    9/4/25 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TWYNEO issued to SOL-GEL TECHNOLOGIES LTD

    Submission status for SOL-GEL TECHNOLOGIES LTD's drug TWYNEO (ORIG-1) with active ingredient TRETINOIN;BENZOYL PEROXIDE has changed to 'Approval' on 07/26/2021. Application Category: NDA, Application Number: 214902, Application Classification: Type 4 - New Combination

    7/27/21 10:39:03 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $5,800 worth of Ordinary Shares (100 units at $58.00) (SEC Form 4)

    4 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)

    2/4/26 4:05:33 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. bought $5,705 worth of Ordinary Shares (100 units at $57.05) (SEC Form 4)

    4 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)

    1/29/26 4:16:32 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. bought $187,356 worth of Ordinary Shares (3,324 units at $56.36) (SEC Form 4)

    4 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)

    1/23/26 5:42:51 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    SEC Filings

    View All

    SEC Form 6-K filed by Sol-Gel Technologies Ltd.

    6-K - Sol-Gel Technologies Ltd. (0001684693) (Filer)

    12/17/25 8:47:45 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Sol-Gel Technologies Ltd.

    6-K - Sol-Gel Technologies Ltd. (0001684693) (Filer)

    11/20/25 8:44:10 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Sol-Gel Technologies Ltd.

    SCHEDULE 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

    11/17/25 4:15:18 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sol-Gel downgraded by Raymond James with a new price target

    Raymond James downgraded Sol-Gel from Strong Buy to Outperform and set a new price target of $4.00 from $6.00 previously

    8/19/24 6:57:49 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Sol-Gel with a new price target

    Jefferies resumed coverage of Sol-Gel with a rating of Hold and set a new price target of $5.50

    10/21/22 7:42:15 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Sol-Gel Technologies with a new price target

    HC Wainwright & Co. reiterated coverage of Sol-Gel Technologies with a rating of Buy and set a new price target of $20.00 from $21.00 previously

    11/15/21 1:18:47 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    Financials

    Live finance-specific insights

    View All

    Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

    An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of SGT-610 (Patidegib gel, 2%), an Orphan Drug candidate with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome and partnered with Galderma to commercialize two approved lar

    3/13/24 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

    Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Phase 1 trial for SGT-210 (erlotinib) demonstrated no systemic absorption-related adverse events; Sol-Gel intends to advance this drug candidate Sol-Gel has cash runway into the second half of 2025 NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with two innovative dermatology products, EPSOLAY and TWYNEO, that were launched in the U.S., SGT-610, which is Phase 3

    5/12/23 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

    Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel's pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndromeA Phase 3 study of SGT-610 is expected to initiate in the second half of 2023, with results expected by the end of 2025The base of recurrent TWYNEO® prescribers was 82% in Q4 2022, while the EPSOLAY® recurrent prescriber base has grown to 64% during the same periodFollowing recent financing, Sol-Gel's cash runway expected to extend into the second half of 2025 NESS ZIONA, Israel, March 10, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company wi

    3/10/23 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    Leadership Updates

    Live Leadership Updates

    View All

    Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

    Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the third quarter ended September

    11/15/24 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribersSol-Gel's cash runway expected to extend through the end of the first quarter of 2024 NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the third quarter ended September 30, 2022 and provided a corporate update. Alon Seri-Levy, PhD, Chief Executive Officer of Sol-Gel, stated, "We are very pleased with the continu

    11/10/22 4:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

    NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today the appointment of Michael Glezin to the position of Vice President, Business Development. In this position, Mr. Glezin will be responsible for identifying new in-licensing business opportunities as well as potential commercial partners for the Company's approved products in ex-US territories. "We are very pleased to have Michael join the Company as we expand our business development efforts," stated Alon Seri-Levy,

    10/3/22 8:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sol-Gel Technologies Ltd.

    SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

    11/14/24 4:37:49 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sol-Gel Technologies Ltd.

    SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

    11/14/24 6:17:23 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Sol-Gel Technologies Ltd. (Amendment)

    SC 13D/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

    4/8/24 9:28:09 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care